VIDEO: Sparsentan reduced proteinuria in patients with focal segmental glomerulosclerosis
Click Here to Manage Email Alerts
Key takeaways:
- Patients treated with sparsentan had a 50% reduction in proteinuria.
- Adverse events were similar to the comparator irbesartan.
PHILADELPHIA — Patients with focal segmental glomerulosclerosis had clinically meaningful and durable reduction in proteinuria with sparsentan treatment, according to phase 3 DUPLEX Trial data presented at ASN Kidney Week, here.
Patients with focal segmental glomerulosclerosis treated with sparsentan (Filspari, Travere Therapeutics) achieved a 50% reduction in proteinuria from baseline compared with a 32% reduction with the active control irbesartan, according to the results.
“The most important results of the study are that it reduced proteinuria significantly compared to the active comparator. More patients treated with sparsentan achieved partial and complete remission. Although the results of the GFR slope between groups were not significant, we believe there still may be a clinical benefit for patients to be treated,” Michelle N. Rheault, MD, of the University of Minnesota, said.
Patients treated with sparsentan also had a consistent and sustained achievement of complete remission of proteinuria in 18.5% vs. 7.5% for patients on irbesartan. Rheault said sparsentan was safe and well-tolerated.
“The drug sparsentan was safe and well-tolerated. There were adverse events that were similar to irbesartan, and we did not see any significant drug-induced liver injury or fluid-retention adverse events,” Rheault said.
References:
Rheault MN, et al. FR-OR1108. Presented at: ASN Kidney Week; Nov. 1-5, 2023; Philadelphia.
Rheault MN, et al. NEJM. 2023;doi:10.1056/NEJMoa2308550.
Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in IgAN and FSGS published in The Lancet and The NEJM respectively and presented at the American Society of Nephrology (ASN) Kidney Week 2023. https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-late-breaking-data-phase-3. Published Nov. 3, 2023. Accessed Nov. 3, 2023.
Collapse
Healio Interviews
Click Here to Manage Email Alerts